Undisclosed CD84-CD3 BsAb / Shanghai Symray Biopharma - LARVOL DELTA

CD84-CD3 bispecific antibody achieves potent anti-leukemic activity with favorable safety profile in Acute Myeloid Leukemia (ASH 2025) - "The #24 BiTE-treated group also showed asignificant reduction in spleen weight at sacrifice (p=0.03). These findings confirm the potential of #24BiTE as an effective therapeutic strategy for targeting CD84-high AML, with promising preclinical efficacyin both xenograft and patient-derived models.ConclusionThis study establishes a strong foundation for the clinical translation of CD84-CD3 bispecific antibodies,demonstrating enhanced targeting specificity and favorable safety profiles for AML treatment."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • CD33 • CD34 • CD9 • CXCL8 • GLI2 • IFNG • IL2 • IL2RA • IL3RA • TNFA